ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Particle Sciences Joins With Hapten

by Ann M. Thayer
February 3, 2014 | APPEARED IN VOLUME 92, ISSUE 5

[+]Enlarge
Credit: Shutterstock
09205-buscon-poisonivycxd.jpg
Credit: Shutterstock

Hapten Sciences and Particle Sciences are working together to move Hapten’s poison ivy, oak, and sumac therapy into clinical trials. According to Memphis-based Hapten, its injectable small-molecule therapy acts like a vaccine to lessen or eliminate contact dermatitis caused by exposure to urushiol oil in the plants. Particle Sciences will manufacture the therapy, which contains urushiol derivatives, for Phase I/II clinical studies scheduled for this year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment